Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Changes of tear in patients with ocular ischemic syndrome

Poster Details

First Author: D. Makhkamova UZBEKISTAN

Co Author(s):                        

Abstract Details

Purpose:

To investigate production, cell composition and pH of tear fluid in patients with ocular ischemic syndrome.

Setting:

Tashkent Institute of Postgraduate Medical Education

Methods:

The main group consisted of 38 patients with verified diagnosis of OIS. The control group included 10 healthy individuals without identical age category ophthalmic pathology. All patients underwent standard and special ophthalmologic examination methods. In addition, studied disorders of production, cell composition, and the pH of the tear fluid.

Results:

in the control group of 20 eyes of healthy individuals revealed: Schirmer's test - 10,1 ± 0.34 mm; cellular composition of tear fluid - abnormal cells are not found; pH - 7,4 ± 0,59 p <0.05. In the main group decrease tear production in the affected eye was observed in all patients. Schirmer test ranged from 4.5 to 9 mm in 3-5 minutes, average 7,2 ± 0,31mm. In the study of the cellular composition of tear fluid in the affected eye cells were visualized in 23 patients and averaged 4,7 ± 0,61. The monocytes were found in the affected eye by an average 5,4 ± 0,27. The pH of the affected eye averaged - 8,9 ± 0,62 (p <0.05).

Conclusions:

In OIS there is a lesion not only the posterior segment of the eyeball, but also of the anterior and the peripheral part of the organ of vision. When OIS decreases the number of production of tear fluid, changing its structure and acid-base balance, resulting in dry eye syndrome, chronic conjunctivitis and keratouveitis.

Financial Disclosure:

NONE

Back to Poster listing